Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats.
作者信息
Jori G, Tomio L, Reddi E, Rossi E, Corti L, Zorat P L, Calzavara F
出版信息
Br J Cancer. 1983 Aug;48(2):307-9. doi: 10.1038/bjc.1983.186.
Abstract
摘要
相似文献
1
Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats.脂质体包裹的卟啉在荷瘤大鼠体内向肿瘤细胞的优先递送。
Br J Cancer. 1983 Aug;48(2):307-9. doi: 10.1038/bjc.1983.186.
2
In vitro and in vivo studies on the interaction of hematoporphyrin and its dimethylester with normal and malignant cells.
Prog Clin Biol Res. 1984;170:471-82.
3
Elimination pathway of hematoporphyrin from normal and tumor-bearing rats.血卟啉在正常大鼠和荷瘤大鼠体内的消除途径。
Tumori. 1982 Aug;68(4):283-6. doi: 10.1177/030089168206800402.
4
Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice.卟啉在荷瘤小鼠体内对不同亚细胞位点的可控靶向作用。
Br J Cancer. 1986 May;53(5):615-21. doi: 10.1038/bjc.1986.104.
5
Distribution of endogenous and injected porphyrins at the subcellular level in rat hepatocytes and in ascites hepatoma.大鼠肝细胞和腹水肝癌细胞中亚细胞水平内源性和注射卟啉的分布
Chem Biol Interact. 1981 Oct;37(1-2):67-75. doi: 10.1016/0009-2797(81)90166-6.
6
[Experimental studies on tumor specificity of hematoporphyrin derivatives. II. Kinetics of hematoporphyrin diacetate and hematoporphyrin disilate in tumor bearing rats].
Nihon Hinyokika Gakkai Zasshi. 1986 Aug;77(8):1324-30. doi: 10.5980/jpnjurol1928.77.8_1324.
7
[Experimental studies on tumor specificity of hematoporphyrin derivatives. I. Preparation and properties of hematoporphyrin diacetate and hematoporphyrin disilate].
Nihon Hinyokika Gakkai Zasshi. 1986 Aug;77(8):1318-23. doi: 10.5980/jpnjurol1928.77.8_1318.
8
[Antitumor effect of liposome-entrapped carboplatin after intraperitoneal administration in rats].[脂质体包裹的卡铂腹腔注射对大鼠的抗肿瘤作用]
Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1753-5.
9
Time dependence of hematoporphyrin distribution in selected tissues of normal rats and in ascites hepatoma.
Tumori. 1979 Aug 31;65(4):425-34. doi: 10.1177/030089167906500402.
10
Haematoporphyrin diacetate: a probe to distinguish malignant from normal tissue by selective fluorescence.二乙酸血卟啉：一种通过选择性荧光区分恶性组织与正常组织的探针。
Br J Exp Pathol. 1980 Aug;61(4):345-50.
引用本文的文献
1
Engineering photodynamics for treatment, priming and imaging.用于治疗、启动和成像的工程光动力学。
Nat Rev Bioeng. 2024 Sep;2(9):752-769. doi: 10.1038/s44222-024-00196-z. Epub 2024 Jun 19.
2
The "" World in Photodynamic Therapy.光动力疗法中的“世界” 。
Austin J Nanomed Nanotechnol. 2014;2(3). Epub 2014 May 29.
3
Liposomal formulations of photosensitizers.脂质体剂型的光敏剂。
Biomaterials. 2019 Oct;218:119341. doi: 10.1016/j.biomaterials.2019.119341. Epub 2019 Jul 10.
4
Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.卟啉脂质组装体和纳米囊泡克服 ABC 转运蛋白介导的癌细胞光动力治疗耐药性。
Cancer Lett. 2019 Aug 10;457:110-118. doi: 10.1016/j.canlet.2019.04.037. Epub 2019 May 6.
5
Cell-Penetrating Protein/Corrole Nanoparticles.穿膜蛋白/卟啉纳米颗粒。
Sci Rep. 2019 Feb 19;9(1):2294. doi: 10.1038/s41598-019-38592-w.
6
Caveolin-3 plays a critical role in autophagy after ischemia-reperfusion.小窝蛋白-3在缺血再灌注后的自噬过程中起关键作用。
Am J Physiol Cell Physiol. 2016 Dec 1;311(6):C854-C865. doi: 10.1152/ajpcell.00147.2016. Epub 2016 Oct 5.
7
Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).用于年龄相关性黄斑变性的高辐照度与光动力疗法（一篇美国眼科学会论文）
Trans Am Ophthalmol Soc. 2008;106:357-82.
8
Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells.大环光敏剂与细胞相互作用的结构和物理化学决定因素。
Eur Biophys J. 2007 Nov;36(8):943-53. doi: 10.1007/s00249-007-0204-9. Epub 2007 Jul 13.
9
In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes.脂质体包裹的酞菁锌的体内荧光及光动力活性
Br J Cancer. 1994 May;69(5):840-5. doi: 10.1038/bjc.1994.163.
10
Photodynamic efficiency of liposome-administered tetramethyl hematoporphyrin in two human bladder cancer cell lines.脂质体给药的四甲基血卟啉在两种人膀胱癌细胞系中的光动力效率
Urol Res. 1995;23(3):151-6. doi: 10.1007/BF00389566.
本文引用的文献
1
Intraperitoneal transplantation of the Yoshida ascites sarcoma and the ascites hepatoma to various American strains of rats.
J Natl Cancer Inst. 1955 Apr;15(5):1367-78.
2
Phototherapy of human tumours using haematoporphyrin derivative.使用血卟啉衍生物对人类肿瘤进行光疗。
Med J Aust. 1980 Nov 1;2(9):489-93. doi: 10.5694/j.1326-5377.1980.tb100708.x.
3
Elimination pathway of hematoporphyrin from normal and tumor-bearing rats.血卟啉在正常大鼠和荷瘤大鼠体内的消除途径。
Tumori. 1982 Aug;68(4):283-6. doi: 10.1177/030089168206800402.
4
In vivo biological activity of the components of haematoporphyrin derivative.血卟啉衍生物各成分的体内生物活性。
Br J Cancer. 1982 Apr;45(4):571-81. doi: 10.1038/bjc.1982.94.
5
Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer.血卟啉衍生物与激光光辐射治疗肺癌
Chest. 1982 Mar;81(3):269-77. doi: 10.1378/chest.81.3.269.
6
Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light.
J Natl Cancer Inst. 1975 Jul;55(1):115-21. doi: 10.1093/jnci/55.1.115.
7
Photochemotherapy of glioma cells by visible light and hematoporphyrin.
Cancer Res. 1975 Sep;35(9):2567-70.
8
Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue.
Cancer Res. 1979 Jan;39(1):146-51.
9
Photoradiation therapy for the treatment of malignant tumors.光辐射疗法治疗恶性肿瘤。
Cancer Res. 1978 Aug;38(8):2628-35.
10
Time dependence of hematoporphyrin distribution in selected tissues of normal rats and in ascites hepatoma.
Tumori. 1979 Aug 31;65(4):425-34. doi: 10.1177/030089167906500402.
Zotero 插件